Why is the need for these tests so urgent? Quantification of plasma concentrations of the
DOACs is critical when assessing their potential contribution to serious bleeding, when …

Aims Edoxaban is an oral, once-daily factor Xa inhibitor that is non-inferior to well-managed
warfarin in patients with atrial fibrillation (AF) for the prevention of stroke and systemic …

Background It is unclear whether edoxaban shows better risk reduction of ischemic stroke,
bleeding, and all-cause mortality than warfarin in Asian patients with nonvalvular atrial …

Rivaroxaban (BAY 59‐7939) is an oral, direct Factor Xa inhibitor in advanced clinical
development for the prevention and treatment of thromboembolic disorders. This was a …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …

Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding
events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the …

Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in phase III clinical development for
stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The shed …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …